Visual bias in the clinical history of pediatric cutaneous drug hypersensitivity reactions
Pediatric Allergy and Immunology · 2026-11 · 37 (11)
DOI: 10.1111/pai.70542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 03.11.2026. Verfasst von Giacomo Gagliardi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Drug Eruptions. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
De‐labeling suspected adverse drug hypersensitivity reactions (DHRs) is a critical goal in clinical practice, as misdiagnosed allergies lead to unnecessary medicalization and unwarranted restrictions on available medications. In children, high‐risk factors for DHRs, such as immediate urticaria, often overlap with common viral rashes, complicating risk stratification. This challenge is compounded by caregiver‐reported histories, which can distort symptom timing and severity. This cross‐sectional comparative questionnaire study with a comparison group evaluated how caregivers and pediatric patients visually recognize common drug‐related skin eruptions and whether non‐clinical variables may affect recognition accuracy.
Methods
Patients and caregivers referred to the Allergy Units of two tertiary care hospitals for suspected DHRs were included. Questionnaires were offered to caregivers and patients aged 7–17. Participants were divided into two groups: patients with suspected DHRs and subjects without a history of DHRs. Enrolled subjects were asked to recognize pictures of maculopapular, micropapular, and urticaria via a multiple‐choice questionnaire.
Results
Data from 405 participants were collected between September 2023 and August 2024. Statistical analysis showed that higher caregiver education and a positive personal history of DHRs and/or urticaria significantly improved recognition accuracy. Nevertheless, nearly half of participants with suspected DHR history misidentified urticaria as micropapular rash. Rash recognition skills did not differ significantly between healthcare and non‐healthcare caregivers.
Conclusion
These findings highlight the need for systematic approaches beyond descriptive histories. Integrating non‐clinical factors into diagnostic frameworks could enhance risk stratification and support safer and more effective allergy workup for de‐labeling suspected DHRs in pediatric patients. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Department of Health Sciences, University of Florence, Florence, Italy.
- Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena, Italy.
ORCID-Profile: Giacomo Gagliardi, Leonardo Tomei, Giulia Liccioli, Simona Barni, Mattia Giovannini, Lucrezia Sarti, Benedetta Pessina, Erika Paladini, Salvatore Grosso, Francesca Mori
Zitieren
APA
Gagliardi, G., Tomei, L., Liccioli, G., Barni, S., Giovannini, M., Sarti, L., Pessina, B., Paladini, E., Ariano, A., Grosso, S., & Mori, F. (2026). Visual bias in the clinical history of pediatric cutaneous drug hypersensitivity reactions. Pediatric Allergy and Immunology, 37(11). https://doi.org/10.1111/pai.70542
Vancouver
Gagliardi G, Tomei L, Liccioli G, Barni S, Giovannini M, Sarti L, et al. Visual bias in the clinical history of pediatric cutaneous drug hypersensitivity reactions. Pediatric Allergy and Immunology. 2026;37(11). doi:10.1111/pai.70542
BibTeX
@article{Gagliardi2026,
author = {Gagliardi, Giacomo and Tomei, Leonardo and Liccioli, Giulia and Barni, Simona and Giovannini, Mattia and Sarti, Lucrezia and Pessina, Benedetta and Paladini, Erika and Ariano, Anna and Grosso, Salvatore and Mori, Francesca},
title = {Visual bias in the clinical history of pediatric cutaneous drug hypersensitivity reactions},
journal = {Pediatric Allergy and Immunology},
year = {2026},
volume = {37},
number = {11},
doi = {10.1111/pai.70542}
}
EUVIMED